Joe Pugliese discusses the Hemophilia Alliance, a not-for-profit organization of federally funded hemophilia treatment centers that is working to ensure its member have the expertise, resources and public support to sustain their integrated clinical and pharmacy services for persons with hemophilia and other bleeding disorders.
Sindhu Ramchandren, MD, discusses updated results from the Vivacity-MG3 clinical trial in patients with generalized myasthenia gravis (MG).
A recent study analyzed patients with primary biliary cholangitis (PBC) who presented with higher IgG levels at diagnosis.
Richard Lafayette, MD, discusses the recent approval of Vanrafia (atrasentan) for patients with IgA nephropathy (IgAN).
A recent study published in the JCEM analyzed the use of digital voice analysis as a biomarker of acromegaly.
Three case studies exploring complexities of diagnosing, treating, and managing patients with various complement-mediated kidney disorders.
Carla Nester, MD, discusses the recent U.S. FDA approval of iptacopan as the first and only treatment of adults with C3 glomerulopathy (C3G).
Paul Bolno, MD, discusses results from the FORWARD-53 clinical trial evaluating WVE-N531 in patients with DMD amenable to exon 53 skipping.
A recent study evaluated outcomes of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients treated with R-GemOx.
A new study highlights the safety and long-term efficacy of TransCOn PTH (palopegteriparatide) to treat hypoparathyroidism.
This study focuses on 75 patients with ADPKD-like phenotypes with 41 different monoallelic predicted loss-of-function IFT140 variants.
